Mild-to-Moderate Active Luminal Crohn’s Disease

Abstract

The management of luminal Crohn’s disease, the most common form of initial presentation of the disease, depends on the location and the severity of the disease. Mild-to-moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients inversely correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies has not been thoroughly evaluated in patients with mild disease.

Efficacy of sulfasalazine in the treatment of generalized lichen planus: randomized double‐blinded clinical trial on 52 patients

“…It has been used most extensively in the treatment of inflammatory bowel disease (i.e. Crohn’s disease and ulcerative colitis), 7 and it has also been used to treat rheumatoid arthritis, 8 psoriasis, 10 ankylosing spondylitis and other spondyloarthropathies 16 …”

“…It has been used most extensively in the treatment of inflammatory bowel disease (i.e. Crohn's disease and ulcerative colitis), 7 and it has also been used to treat rheumatoid arthritis, 8 psoriasis, 10 ankylosing spondylitis and other spondyloarthropathies. 16 The advice of sulfasalazine as treatment for LP for the first time was described by Bauzá et al 15 The current study was the second one and confirms the results of the previous study that have demonstrated a favourable clinical response of patients with LP to sulfasalazine.…”

“…Sulfasalazine is degraded by bacteria in the colon into two products: 5‐aminosalicylic acid (5ASA) and sulfapyridine 5 . Sulfasalazine has both immunosuppressive and immunomodulatory effects 6 and has been used for the treatment of inflammatory bowel disease, 7 rheumatoid arthritis 8 and other diseases including pustular psoriasis, 9 arthropathic psoriasis, 10 dermatitis herpetiformis, 11 systemic lupus erythematosus, 12 scleroderma 13 and acne 14 . Successful treatment of LP with sulfasalazine was first reported by Bauzá et al.…”